Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

523 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study.
Deodhar A, Conaghan PG, Kvien TK, Strand V, Sherif B, Porter B, Jugl SM, Gandhi KK; MEASURE 2 study group. Deodhar A, et al. Among authors: strand v. Clin Exp Rheumatol. 2019 Mar-Apr;37(2):260-269. Epub 2018 Jul 19. Clin Exp Rheumatol. 2019. PMID: 30148436 Clinical Trial.
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Furst DE, et al. Among authors: strand v. J Rheumatol. 2003 Dec;30(12):2563-71. J Rheumatol. 2003. PMID: 14719195 Clinical Trial.
An integrated analysis of five double-blind, randomized controlled trials evaluating the safety and efficacy of a hyaluronan product for intra-articular injection in osteoarthritis of the knee.
Strand V, Conaghan PG, Lohmander LS, Koutsoukos AD, Hurley FL, Bird H, Brooks P, Day R, Puhl W, Band PA. Strand V, et al. Osteoarthritis Cartilage. 2006 Sep;14(9):859-66. doi: 10.1016/j.joca.2006.02.012. Epub 2006 Apr 19. Osteoarthritis Cartilage. 2006. PMID: 16626978 Free article.
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO 3rd, Hughes M, Altman D, Buyse M, Galbraith S, Wells G. Lassere MN, et al. Among authors: strand v. J Rheumatol. 2007 Mar;34(3):607-15. J Rheumatol. 2007. PMID: 17343307
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A. Strand V, et al. Arthritis Res Ther. 2009;11(6):R170. doi: 10.1186/ar2859. Epub 2009 Nov 12. Arthritis Res Ther. 2009. PMID: 19909548 Free PMC article. Clinical Trial.
A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis.
Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE. Genovese MC, et al. Among authors: strand v. J Rheumatol. 2011 May;38(5):846-54. doi: 10.3899/jrheum.100602. Epub 2011 Feb 1. J Rheumatol. 2011. PMID: 21285160 Clinical Trial.
523 results